# Josh Carle

> Josh Carle is the Chief Business Officer of Hinge Bio, a Burlingame, California biotech building multivalent, multispecific antibody therapies on its GEM-DIMER platform. A dealmaker by trade, he has led or advised more than fifty strategic transactions worth over $2 billion in disclosed deal value, moving from Pfizer Oncology and Daiichi Sankyo to immuno-oncology startup Triumvira before joining Hinge Bio in January 2023 to steer its lead lupus program toward the clinic.

- **Role:** Chief Business Officer at Hinge Bio
- **Organizations:** Hinge Bio, Triumvira Immunologics, Pfizer, Daiichi Sankyo, Clearview Projects
- **Nationality:** American
- **Education:** B.A. in Economics, University of Pennsylvania, M.B.A., Villanova School of Business
- **Known for:** Led or advised more than fifty potential strategic transactions, Executed greater than $2 billion in disclosed deal value and committed R&D funds, At Triumvira, executed a clinical collaboration for a leading checkpoint inhibitor and in-licensed a novel antibody

## Career timeline

- **earlier** — Business development at Clearview Projects, a strategic advisory firm focused on licensing/M&A for biopharma
- **earlier** — Roles of increasing responsibility in business development at Daiichi Sankyo
- **earlier** — Vice President, Business Development at Pfizer, driving BD strategy and licensing/M&A for Pfizer Oncology
- **before 2023** — Vice President, Business Development at Triumvira Immunologics; executed a clinical collaboration for a checkpoint inhibitor and in-licensed a novel antibody
- **2023** — Joined Hinge Bio as Chief Business Officer (announced January 2023)
- **2025** — Hinge Bio closed a $30M Series A' led by Point72 to advance lead candidate HB2198 toward a Phase 1 lupus trial

## Achievements

- Led or advised more than fifty potential strategic transactions
- Executed greater than $2 billion in disclosed deal value and committed R&D funds
- At Triumvira, executed a clinical collaboration for a leading checkpoint inhibitor and in-licensed a novel antibody
- Helped position Hinge Bio for a $30M Series A' led by Point72 (2025)

## Latest updates

- **2025-01** — Hinge Bio raised a $30 million Series A' led by Point72 with Ridgeback Capital, InVivium Capital and Lightswitch Capital to advance HB2198 into a Phase 1 lupus trial.
- **2023-01** — Joined Hinge Bio as Chief Business Officer as the company expanded its senior management team to drive GEM-DIMER programs toward clinical development.

## Links

- Website: https://hingebio.com
- LinkedIn: http://www.linkedin.com/in/josh-carle

---

Profile page: https://yespress.io/josh-carle
Published by YesPress — https://yespress.io
Last updated: 2026-06-03